Impact of nonalcoholic fatty liver disease status change on antiviral efficacy of nucleos(t)ide analogues in HBeAg‐positive chronic hepatitis B

Data on the dynamic changes in chronic hepatitis B (CHB) patients with nonalcoholic fatty liver disease (NAFLD) during antiviral therapy are scarce. We aimed to investigate the evolution of NAFLD status change in CHB patients treated with nucleos(t)ide analogues (NAs) and its influence on therapeuti...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medical virology 2023-02, Vol.95 (2), p.e28501-n/a
Main Authors: Tang, Yanhua, Fan, Rong, Lan, Zhixian, Xie, Qing, Zhang, Jiping, Liang, Xieer, Wang, Hao, Tan, Deming, Cheng, Jun, Chen, Shijun, Ning, Qin, Bai, Xuefan, Xu, Min, Chen, Xinyue, Niu, Junqi, Shi, Junping, Ren, Hong, Gao, Zhiliang, Wang, Maorong, Dou, Xiaoguang, Hou, Jinlin, Sun, Jian
Format: Article
Language:English
Subjects:
Antiviral agents
Antiviral Agents - therapeutic use
Biopsy
Fatty liver
Fibrosis
Hepatitis
Hepatitis B
Hepatitis B e antigen
Hepatitis B e Antigens - analysis
Hepatitis B virus
Hepatitis B, Chronic - drug therapy
Humans
Interferon
Liver
liver biopsy
Liver diseases
Non-alcoholic Fatty Liver Disease
nucleos(t)ide analogues
Remission
Retrospective Studies
Seroconversion
Subgroups
Therapy
Treatment Outcome
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Data on the dynamic changes in chronic hepatitis B (CHB) patients with nonalcoholic fatty liver disease (NAFLD) during antiviral therapy are scarce. We aimed to investigate the evolution of NAFLD status change in CHB patients treated with nucleos(t)ide analogues (NAs) and its influence on therapeutic outcomes. This retrospective study included 164 HBeAg‐positive CHB patients from a randomized controlled trial who were treated with NAs for 104 weeks and underwent paired liver biopsies. Histological evaluation was performed at baseline and Week 104. The patients were divided into four groups according to NAFLD status changes. From baseline to Week 104, the overall percentage of CHB patients with concurrent NAFLD increased from 17.1% to 26.2% (p = 0.044). Among them, 7 of 28 patients (25.0%) with NAFLD at baseline showed NAFLD remission at week 104, while 22 of 136 patients (16.2%) without NAFLD at baseline developed new‐onset NAFLD. In subgroup analyses, the new‐onset and sustained NAFLD groups showed significantly lower rates of biochemical response at week 104 as compared to the sustained non‐NAFLD group (77.3% and 57.1% vs. 93.9%, respectively; all p 
ISSN:0146-6615
1096-9071
DOI:10.1002/jmv.28501